Comparing the efficacy of regen-cov,remdesivir,and favipiravir in reducing invasive mechanical ventilation need in hospitalized COVID-19 patients  

作　　者：Sahar Kmal Hegazy Samar Tharwat Ahmed Hosny Hassan 

机构地区：[1]Clinical Pharmacy Department,Faculty of Pharmacy,Tanta University,Tanta 31511,Egypt [2]Rheumatology and Immunology Unit,Internal Medicine Department,Faculty of Medicine,Mansoura university,Mansoura 35511,Egypt [3]Clinical Pharmacy Department,Mansoura University Hospital,Mansoura 35511,Egypt

出　　处：《World Journal of Clinical Cases》2023年第26期6105-6121,共17页世界临床病例杂志

摘　　要：BACKGROUND Coronavirus disease 2019(COVID-19)pandemic stimulates research works to find a solution to this crisis from starting 2020 year up to now.With ending of the 2021-year,various advances in pharmacotherapy against COVID-19 have emerged.Regarding antiviral therapy,casirivimab and imdevimab antibody combination is a type of new immunotherapy against COVID-19.Standard antiviral therapy against COVID-19 includes Remdesivir and Favipiravir.AIM To evaluate the efficacy of antibodies cocktail(casirivimab and imdevimab)compared to standard antiviral therapy in reducing the need for invasive mechanical ventilation(IMV).METHODS 265 COVID-19 polymerase chain reaction confirmed patients with indication for antiviral therapy were included in this study and were divided into 3 groups(1:2:2):Group A:REGN3048-3051 antibodies cocktail(casirivimab and imdevimab),group B:Remdesivir,group C:Favipiravir.The study design is a single-blind nonrandomized controlled trial Mansoura University Hospital owns the study’s drugs.The duration of the study was about 6 mo after ethical approval.RESULTS Casirivimab and imdevimab achieve less need for O2 therapy and IMV,with less duration of this need than remdesivir and favipiravir.CONCLUSION Group A(casirivimab and imdevimab)achieve better clinical outcomes than groups B(remdesivir)and C(favipiravir)intervention groups.

关 键 词：ANTIVIRALS Casirivimab and imdevimab Coronavirus disease 2019 Favipiravir Remdesivir 

分 类 号：R563.1[医药卫生—呼吸系统]